FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on limited data from 2 clinical trials that enrolled VZV-seronegative or low seropositive subjects (30 years of age or older) receiving live attenuated zoster vaccine, injection site and systemic adverse experiences were generally similar to those reported by other subjects who received ZOSTAVAX in clinical trials, with 2 of the 27 subjects reporting fever.
Croatian: Odrasli seronegativni na virus varicella-zoster (VZV) Na temelju ograničenih podataka iz 2 klinička ispitivanja koja su uključila ispitanike (u dobi od 30 godina ili starije) seronegativne ili nisko seropozitivne na VZV koji su primili živo atenuirano cjepivo protiv zostera, nuspojave na mjestu injekcije i sistemske nuspojave bile su općenito slične onima koje su prijavili drugi ispitanici koj su primili ZOSTAVAX u kliničkim ispitivanja, s time da je 2 od 27 ispitanika prijavilo vrućicu.
English: Number of zoster confirmed cases
Croatian: Broj potvrđenih slučajeva herpes zostera
English: Adults on chronic/maintenance systemic corticosteroids In subjects 60 years of age or older who were receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks prior to enrollment, and 6 weeks or more following vaccination, the safety profile was generally comparable to that seen in the Adverse Event Monitoring Substudy of the SPS (see sections 4.3 and 5.1).
Croatian: U ispitanika u dobi od 60 godina ili starijih koji su bili primali kroničnu terapiju/ terapiju održavanja sistemskim kortikosteroidima u dnevnoj dozi koja je odgovarala 5 do 20 mg prednizona tijekom najmanje 2 tjedna prije uključenja i 6 ili više tjedana nakon cijepljenja, sigurnosni profil općenito je bio usporediv s onim opaženim u Podispitivanju praćenja štetnih događaja u sklopu ispitivanja SPS (vidjeti dijelove 4.3 i 5.1).
English: The estimated vaccine efficacy during the LTPS follow-up period was 21% (95% CI: [11 to 30%]) for zoster incidence, 35% (95% CI: [9 to 56%]) for PHN incidence and 37% (95% CI: [27 to 46%]) for zoster BOI.
Croatian: Procijenjena djelotvornost cjepiva tijekom razdoblja praćenja u podispitivanju LTPS bila je 21% (95% CI: [11 do 30%]) za incidenciju herpes zostera, 35% (95% CI: [9 do 56%]) za incidenciju PHN-a te 37% (95% CI: [27 do 46%]) za rezultat na ljestvici BOI herpes zostera.
English: Merck Sharp & Dohme Corp. Sumneytown Pike West Point
Croatian: Sumneytown Pike West Point
English: ZOSTAVAX was administered either subcutaneously (SC) or intramuscularly (IM) in subjects 50 years of age or older (see section 5.1).
Croatian: ZOSTAVAX je bio primijenjen ili supkutano (s.c.) ili intramuskularno (i.m.) ispitanicima u dobi od 50 godina ili starijima (vidjeti dio 5.1).
English: ZOSTAVAX is indicated for prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).
Croatian: ZOSTAVAX je indiciran za prevenciju herpes zostera ("zoster") i postherpetične neuralgije (PHN) prouzročene herpes zosterom.
English: The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Croatian: Prije primjene, rekonstituirano cjepivo treba vizualno pregledati da ne sadrži strane čestice i/ili da nema neprirodan fizički izgled.
English: Common (≥1/100 to <1/10);
Croatian: Često (≥1/100 i <1/10);
English: Impaired vision occurred in 2 subjects vaccinated with ZOSTAVAX vs. 9 who received placebo.
Croatian: Vid je bio narušen u 2 ispitanika cijepljena cjepivom ZOSTAVAX naspram 9 koji su primili placebo.
English: Before mixing with the solvent, the powder is a white to off-white compact crystalline plug.
Croatian: Prije miješanja s otapalom, prašak je bijela do bjelkasta kompaktna kristalična krutina.
English: The estimated vaccine efficacy during the STPS follow-up period was 40% (95% CI: [18 to 56%]) for zoster incidence, 60% (95% CI: [-10 to 87%]) for PHN incidence and 50% (95% CI: [14 to 71%]) for zoster BOI.
Croatian: Procijenjena djelotvornost cjepiva tijekom razdoblja praćenja u podispitivanju STPS bila je 40% (95% CI:[18 do 56%]) za incidenciju herpes zostera, 60% (95% CI: [-10 do 87%]) za incidenciju PHN te 50% (95% CI: [14 do 71%]) za rezultat na ljestvici BOI herpes zostera.
English: Reduction of zoster pain severity-by-duration in vaccinated individuals who developed zoster With regard to the acute pain (pain between 0-30 days) there was no statistically significant difference between the vaccine group and the placebo group.
Croatian: S obzirom na akutnu bol (bol između 0-30 dana), nije bilo statistički značajne razlike između cijepljene skupine i skupine koja je primila placebo.
English: The need for a booster dose is not known.
Croatian: Nije poznato je li potrebno docjepljivanje.
English: For instructions on reconstitution of the medicinal product before administration see section 6.6.
Croatian: Za upute o rekonstituciji lijeka prije primjene vidjeti dio 6.6.
English: HIV-infected adults with conserved immune function In a double-blind, placebo-controlled randomised clinical trial, ZOSTAVAX was administered to HIV-infected adults (18 years of age or older; median age 49 years) on appropriate antiretroviral therapy with conserved immune function (CD4+ T cell count ≥ 200 cells/µL).
Croatian: Odrasli zaraženi HIV-om s očuvanom imunološkom funkcijom U dvostruko slijepom, placebom kontroliranom randomiziranom kliničkom ispitivanju, ZOSTAVAX je bio primijenjen u odraslih zaraženih HIV-om (u dobi od 18 godina ili starijih; medijan dobi: 49 godina) s očuvanom imunološkom funkcijom (broj CD4+ T stanica ≥200 stanica/µl) na odgovarajućoj antiretrovirusnoj terapiji.
English: The concomitant use of ZOSTAVAX and a 23-valent pneumococcal polysaccharide vaccine resulted in reduced immunogenicity of ZOSTAVAX in a small clinical trial.
Croatian: U malom kliničkom ispitivanju istodobna primjena cjepiva ZOSTAVAX sa 23-valentnim pneumokoknim polisaharidnim cjepivom rezultirala je smanjenom imunogenošću cjepiva ZOSTAVAX.
English: Sucrose, hydrolysed gelatin, urea, sodium chloride, potassium dihydrogen phosphate, potassium chloride, monosodium L-glutamate monohydrate, disodium phosphate, sodium hydroxide.
Croatian: Saharoza, hidrolizirana želatina, urea, natrijev klorid, kalijev dihidrogenfosfat, kalijev klorid, natrijev L-glutamat hidrat, natrijev hidrogenfosfat, natrijev hidroksid.
English: In an open-label study, ZOSTAVAX was administered as: (1) a booster dose to 201 zoster history-negative subjects 70 years of age or older who had received a first dose approximately 10 years previously as participants in the SPS, and (2) a first dose to 199 zoster history-negative subjects 70 years of age or older.
Croatian: U jednom otvorenom ispitivanju, ZOSTAVAX je bio primijenjen: (1) za docjepljivanje u 201 ispitanika u dobi od 70 godina ili starijih bez herpes zostera u anamnezi koji su primili prvu dozu približno 10 godina ranije kao sudionici ispitivanja SPS i (2) kao prva doza u 199 ispitanika u dobi od 70 godina ili starijih bez herpes zostera u anamnezi.
English: Additional adverse reactions, spontaneously reported through post-marketing surveillance, are also included in Table 1.
Croatian: Tablica 1 također uključuje i dodatne nuspojave spontano prijavljene tijekom praćenja nakon stavljanja cjepiva u promet.
English: After reconstitution, 1 dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live, attenuated) ≥19,400 PFU
Croatian: Nakon pripreme, 1 doza (0,65 ml) sadrži: Varicella-zoster virus, soj Oka/Merck (živi, atenuirani) ≥19 400 PFU
English: In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomised to receive a single dose of ZOSTAVAX either concomitantly (N=237), or nonconcomitantly (N=236) with 23-valent pneumococcal polysaccharide vaccine.
Croatian: U dvostruko slijepom, kontroliranom kliničkom ispitivanju 473 odrasle osobe u dobi od 60 i više godina bile su randomizirane u skupinu koja je primila jednokratnu dozu cjepiva ZOSTAVAX istodobno (N=237) odnosno u skupinu koja ga nije primila istodobno (N=236) s 23-valentnim pneumokoknim polisaharidnim cjepivom.
English: At four weeks post-vaccination, the VZV-specific immune responses following concomitant use were not similar to the VZV-specific immune responses following nonconcomitant administration.
Croatian: Četiri tjedna nakon cijepljenja, specifični imunološki odgovor protiv virusa varicella-zoster nastao nakon istodobne primjene nije bio sličan specifičnom imunološkom odgovoru protiv virusa varicella-zoster kad se ne primjenjuje istodobno.
English: Incidence rate of zoster per person years
Croatian: Stopa incidencije herpes zostera na osoba godina
English: One pack of ZOSTAVAX contains a vial and a pre-filled syringe with or without attached needles.
Croatian: Jedno pakiranje cjepiva ZOSTAVAX sadrži bočicu i napunjenu štrcaljku s pričvršćenom ili zasebnom iglom.
English: The ZEST study was a placebo-controlled, double-blind clinical trial in which 22,439 subjects were randomised to receive a single dose of either ZOSTAVAX or placebo and were followed for the development of zoster for a median of 1.3 years (range 0 to 2 years).
Croatian: Ispitivanje ZEST bilo je placebom kontrolirano, dvostruko slijepo kliničko ispitivanje u kojem je 22 439 ispitanika bilo randomizirano u skupine koje su primile jednu dozu cjepiva ZOSTAVAX ili placeba i praćene zbog razvoja herpes zostera tijekom medijana od 1,3 godine (raspon: od 0 do 2 godine).
English: Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Croatian: United Kingdom Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
English: Subjects on chronic/maintenance systemic corticosteroids In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 206 subjects 60 years of age or older who were receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks prior to enrollment, and 6 weeks or more following vaccination to assess the immunogenicity and safety profile of ZOSTAVAX.
Croatian: U dvostruko slijepom, placebom kontroliranom, randomiziranom kliničkom ispitivanju, ZOSTAVAX je bio primijenjen u 206 ispitanika u dobi od 60 godina ili starijih koji su primali kroničnu terapiju/terapiju održavanja sistemskim kortikosteroidima u dnevnoj dozi koja je odgovarala 5 do 20 mg prednizona tijekom najmanje 2 tjedna prije uključenja u ispitivanje te 6 tjedana ili više nakon cijepljenja kako bi se procijenili imunogenost i sigurnosni profil cjepiva ZOSTAVAX.
English: ZOSTAVAX significantly decreased the incidence of Post-herpetic Neuralgia (PHN) compared with placebo (see Table 4).
Croatian: ZOSTAVAX je značajno smanjio incidenciju postherpetične neuralgije (PHN) u usporedbi s placebom (vidjeti tablicu 4).
English: ZOSTAVAX with solvent for reconstitution supplied in a vial:
Croatian: ZOSTAVAX s otapalom za rekonstituciju dostupnim u napunjenoj štrcaljki:
English: VE estimates by age at vaccination and average VE estimates over the first 3 and 5 years postvaccination are shown below (see Table 7).
Croatian: Procjene učinkovitosti cjepiva prema dobi pri cijepljenju i prosječne procjene učinkovitosti cjepiva tijekom prvih 3, odnosno 5 godina nakon cijepljenja prikazane su niže (vidjeti Tablicu 7).
English: VE estimates by age at vaccination and average VE estimates over the first 3 and 5 years postvaccination are shown below (see Table 6).
Croatian: Procjene učinkovitosti cjepiva prema dobi pri cijepljenju i prosječne procjene učinkovitosti cjepiva tijekom prvih 3, odnosno 5 godina nakon cijepljenja prikazane su niže (vidjeti Tablicu 6).
English: Rare (≥1/10,000 to <1/1,000);
Croatian: Rijetko (≥1/10 000 i <1/1000);
English: To reconstitute the vaccine, inject all the solvent in the pre-filled syringe into the vial of lyophilised vaccine and gently agitate to mix thoroughly.
Croatian: Za rekonstituciju cjepiva, ubrizgajte cijeli sadržaj otapala napunjene štrcaljke u bočicu s liofiliziranim cjepivom te nježnim mućkanjem temeljito pomiješajte.
English: Table 1 presents vaccine-related injection-site and systemic adverse reactions reported at a significantly greater incidence in the vaccine group versus the placebo group within 42 days postvaccination in the ZOSTAVAX Efficacy and Safety trial (ZEST) study and in the Adverse Event Monitoring Substudy of Shingles Prevention Study (SPS).
Croatian: Tablica 1 prikazuje reakcije na mjestu injekcije i sistemske nuspojave povezane s cjepivom prijavljene u značajno većoj incidenciji u skupini koja je primila cjepivo nego u skupini koja je primila placebo unutar 42 dana nakon cijepljenja u ispitivanju djelotvornosti i sigurnosti cjepiva ZOSTAVAX (engl.
English: Table 5: Reduction of the zoster-associated pain by the BOI
Croatian: Tablica 5: Smanjenje boli povezane s herpes zosterom prema rezultatu na ljestvici BOI
English: Table 2: Efficacy of ZOSTAVAX on zoster incidence compared with placebo in the ZEST trial in subjects 50 to 59 years of age*
Croatian: Tablica 2: Djelotvornost cjepiva ZOSTAVAX u pogledu incidencije herpes zostera u usporedbi s placebom u ispitivanju ZEST u ispitanika u dobi od 50 do 59 godina*
English: Table 6: VE† of ZOSTAVAX against HZ over the study period and on average over 3 and 5 years, by age at vaccination.
Croatian: Tablica 6: VE† cjepiva ZOSTAVAX protiv herpes zostera tijekom razdoblja ispitivanja i u prosjeku tijekom 3, odnosno 5 godina, prema dobi pri cijepljenju.
English: Adults with a history of herpes zoster (HZ) prior to vaccination ZOSTAVAX was administered to subjects 50 years of age or older with a history of herpes zoster (HZ) prior to vaccination (see section 5.1).
Croatian: Odrasli koji su imali herpes zoster (HZ) u anamnezi prije cijepljenja ZOSTAVAX je bio primijenjen ispitanicima u dobi od 50 godina ili starijima koji su imali herpes zoster (HZ) u anamnezi prije cijepljenja (vidjeti dio 5.1).
English: Within ZEST, immune responses to vaccination were evaluated in a random 10% subcohort (n=1,136 for ZOSTAVAX and n=1,133 for placebo) of the subjects enrolled in the ZEST.
Croatian: Ispitivanje djelotvornosti i sigurnosti cjepiva ZOSTAVAX (ZEST) U sklopu ispitivanja ZEST, imunološki odgovor na cjepivo procijenio se u nasumično odabranoj podkohorti s 10% ispitanika (n=1136 za ZOSTAVAX i n=1133 za placebo) uključenih u ispitivanje ZEST.
English: Zostavax persistence of protection
Croatian: Trajnost zaštite cjepivom ZOSTAVAX:
English: In a double-blind, controlled clinical trial, 762 adults 50 years of age and older were randomised to receive a single dose of ZOSTAVAX administered either concomitantly (N=382) or nonconcomitantly (N=380) with inactivated split influenza vaccine.
Croatian: U dvostruko slijepom, kontroliranom, kliničkom ispitivanju, 762 odrasle osobe u dobi od 50 i više godina bile su randomizirane u skupinu koja je primila jednokratnu dozu cjepiva ZOSTAVAX istodobno (N=382) odnosno u skupinu koja ga nije primila istodobno (N=380) s inaktiviranim cjepivom protiv gripe koje sadrži samo površinske antigene virusa gripe (tzv. split cjepivo).
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava limfadenopatija (vratni, pazušni)
English: The VZV-specific immune responses to both vaccines at 4 weeks post-vaccination were similar, whether administered concomitantly or nonconcomitantly.
Croatian: Specifičan imunološki odgovor protiv virusa varicella-zoster nastao na oba cjepiva 4 tjedna nakon cijepljenja bio je sličan bez obzira na to jesu li cjepiva bila primijenjena istodobno ili ne.
English: The persistence of protection following vaccination has been evaluated through longer-term follow-up in Short-term Persistence Substudy (STPS) and Long-term Persistence Substudy (LTPS) and supports the continued benefit of ZOSTAVAX throughout the follow-up periods studied.
Croatian: Longterm Persistence Substudy, LTPS), a nalazi podupiru kontinuiranu korist od cjepiva ZOSTAVAX tijekom cijelog ispitivanog razdoblja praćenja.
English: The frequency of vaccine-related adverse experiences after the second dose of ZOSTAVAX was generally similar to that seen with the first dose.
Croatian: Učestalost nuspojava povezanih s cjepivom nakon druge doze cjepiva ZOSTAVAX bila je općenito slična onoj opaženoj uz prvu dozu.
English: ZOSTAVAX contains sodium
Croatian: ZOSTAVAX sadrži natrij
English: How to use ZOSTAVAX
Croatian: Kako primjenjivati ZOSTAVAX
English: The VZV-specific immune responses to vaccine 6 weeks post-vaccination was comparable in the booster dose and first dose group.
Croatian: Specifični imunološki odgovor protiv virusa varicella-zoster nastao na cjepivo 6 tjedana nakon cijepljenja zbog docjepljivanja bio je usporediv s onim u skupini koja je primila prvu dozu.
English: Table 3: Efficacy of ZOSTAVAX on zoster incidence compared with placebo in the SPS in subjects 60 years of age and older*
Croatian: Tablica 3: Djelotvornost cjepiva ZOSTAVAX u pogledu incidencije herpes zostera u usporedbi s placebom u ispitivanju SPS u ispitanika u dobi od 60 godina i starijih*
English: Shingles Prevention Study (SPS) in Subjects 60 years of age and older:
Croatian: † u ispitivanju SPS u ispitanika u dobi od 60 godina i starijih
English: The frequency of vaccine-related adverse experiences after the booster dose of ZOSTAVAX was generally similar to that seen with the first dose.
Croatian: Učestalost nuspojava povezanih s cjepivom nakon docjepljivanja cjepivom ZOSTAVAX bila je općenito slična onoj opaženoj kod primjene prve doze.
English: In another study, ZOSTAVAX was administered as a booster dose to HZ history-negative subjects 70 years of age or older who had received a first dose approximately 10 years previously, and as a first dose to HZ history-negative subjects 70 years of age or older (see section 5.1).
Croatian: U drugom je ispitivanju ZOSTAVAX bio primijenjen kao dodatna doza zbog docjepljivanja ispitanicima u dobi od 70 godina ili starijima koji nisu imali herpes zoster u anamnezi i koji su primili prvu dozu približno 10 godina ranije, te kao prva doza ispitanicima u dobi od 70 godina ili starijima koji nikad prije nisu imali herpes zoster (vidjeti dio 5.1).
English: Sucrose, hydrolysed gelatin, sodium chloride, potassium dihydrogen phosphate, potassium chloride, monosodium L-glutamate monohydrate, disodium phosphate, sodium hydroxide (to adjust pH), and urea.
Croatian: Prašak saharoza, hidrolizirana želatina, natrijev klorid, kalijev dihidrogenfosfat, kalijev klorid, natrijev Lglutamat hidrat, natrijev hidrogenfosfat, natrijev hidroksid (za podešavanje pH) i urea.
English: Compared with placebo, ZOSTAVAX induced a higher VZV-specific immune response at 6 weeks post-vaccination.
Croatian: U usporedbi s placebom, ZOSTAVAX je izazvao viši specifični imunološki odgovor protiv virusa varicella-zoster 6 tjedana nakon cijepljenja.
English: Concomitant administration
Croatian: Istodobna primjena
English: Withdraw the entire contents of the reconstituted vaccine using the same syringe.
Croatian: Izvucite cijeli sadržaj rekonstituiranog cjepiva koristeći istu štrcaljku.
English: Subjects with a history of herpes zoster (HZ) prior to vaccination In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 100 subjects 50 years of age or older with a history of herpes zoster prior to vaccination to assess immunogenicity and safety (see section 4.8) of ZOSTAVAX.
Croatian: U dvostruko slijepom, placebom kontroliranom, randomiziranom kliničkom ispitivanju, ZOSTAVAX je bio primijenjen u 100 ispitanika u dobi od 50 godina ili starijih koji su prije cijepljenja u anamnezi imali herpes zoster kako bi se procijenila imunogenost i sigurnost cjepiva ZOSTAVAX (vidjeti dio 4.8).
English: When completely reconstituted, the vaccine is a semi-hazy to translucent, off-white to pale yellow liquid.
Croatian: Kad se potpuno rekonstituira, cjepivo je blago mutna do prozirna, bjelkasta do svijetložuta tekućina.
English: • Uncommon (may affect up to 1 in 100 people): Nausea; swollen gland (neck, armpit)
Croatian: • Manje često (mogu se javiti u do 1 na 100 osoba): mučnina, otečene limfne žlijezde (na vratu, u pazuhu)
English: The safety and efficacy of ZOSTAVAX have not been established in adults who are known to be infected with HIV with or without evidence of immunosuppression (see section 4.3) however, a phase II safety and immunogenicity study in HIV-infected adults with conserved immune function (CD 4+T cell count ≥ 200 cells/µL) has been completed (see sections 4.8 and 5.1).
Croatian: Međutim, završeno je ispitivanje faze II sigurnosti i imunogenosti u odraslih zaraženih HIV-om s očuvanom imunološkom funkcijom (broj CD 4+T stanica ≥ 200 stanica/µl) (vidjeti dijelove 4.8 i 5.1).
English: ZOSTAVAX induced a significantly higher VZV-specific immune response at 4 weeks post-vaccination, compared with placebo.
Croatian: ZOSTAVAX je izazvao značajno viši specifični imunološki odgovor protiv virusa varicellazoster 4 tjedna nakon cijepljenja, u usporedbi s placebom.
English: To reconstitute the vaccine, use the solvent provided.
Croatian: Za rekonstituciju cjepiva uporabite priloženo otapalo.
English: What is shingles?
Croatian: Što je herpes zoster?
English: ZOSTAVAX is a vaccine used to prevent shingles (zoster) and zoster-related post-herpetic neuralgia (PHN), the long-lasting nerve pain that follows shingles.
Croatian: ZOSTAVAX je cjepivo za sprečavanje herpes zostera i postherpetične neuralgije (PHN) povezane sa herpes zosterom, tj. dugotrajne neuropatske boli nakon herpes zostera.
English: Mean BOI score
Croatian: Srednji rezultat na ljestvici BOI
English: Concurrent administration of ZOSTAVAX and anti-viral medications known to be effective against VZV has not been evaluated.
Croatian: Istodobna primjena cjepiva ZOSTAVAX s antivirusnim lijekovima za koje se zna da djeluju protiv varicella-zoster virusa nije procijenjena.
English: Inject all the solvent into the vial of lyophilised vaccine.
Croatian: Ubrizgajte otapalo u bočicu s liofiliziranim cjepivom.
English: Uncommon (≥1/1,000 to <1/100);
Croatian: Manje često (≥1/1000 i <1/100);
English: ZOSTAVAX significantly decreased the incidence of zoster compared to placebo (see Table 2).
Croatian: ZOSTAVAX je značajno smanjio incidenciju herpes zostera u usporedbi s placebom (vidjeti tablicu 2).
English: ZOSTAVAX is not recommended to be administered to pregnant women.
Croatian: Primjena cjepiva ZOSTAVAX se ne preporučuje u trudnica.
English: Herpes zoster/herpes zoster-like rashes and Varicella/varicella-like rashes in clinical trials In clinical trials the number of herpes zoster/herpes zoster-like rashes within the 42-day postvaccination was low in both ZOSTAVAX and placebo groups.
Croatian: U kliničkim je ispitivanjima broj slučajeva osipa herpes zostera/nalik herpes zosteru unutar 42 dana nakon cijepljenja bio nizak i u skupini cijepljenoj cjepivom ZOSTAVAX i u skupini koja je primala placebo.
English: One or 2 separate needles may be available in the secondary packaging of the presentation containing the pre-filled syringe without attached needle.
Croatian: Jedna ili 2 zasebne igle mogu biti priložene u sekundarnom pakiranju koje sadrži napunjenu štrcaljku bez pričvršćene igle.
English: When reconstituted, ZOSTAVAX is a semi-hazy to translucent, off-white to pale yellow liquid.
Croatian: Nakon rekonstitucije, ZOSTAVAX je blago zamućena do prozirna, bjelkasta do svijetložuta tekućina.
English: ZOSTAVAX significantly decreased the incidence of zoster compared with placebo (see Table 3).
Croatian: ZOSTAVAX je značajno smanjio incidenciju herpes zostera u usporedbi s placebom (vidjeti tablicu 3).
English: Withdraw the entire content of the reconstituted vaccine using the same syringe.
Croatian: Izvucite cijeli sadržaj rekonstituiranog cjepivakoristeći istu štrcaljku.